研究顯示減肥藥有助於改善心理健康
Study Links Weight Loss Drugs to Improved Mental Health
最近的研究顯示，GLP-1受體促效劑，例如司美格魯肽，可能提供超越生理減重的效益。
Recent research suggests that GLP-1 receptor agonists, such as semaglutide, may offer benefits beyond physical weight loss.
包括2026年刊載於《刺胳針精神病學》(The Lancet Psychiatry)的研究報告指出，這些藥物與精神科住院風險降低42%有關。
Studies, including a 2026 report in The Lancet Psychiatry, indicate that these medications are linked to a 42% lower risk of psychiatric hospitalizations.
患者通報在憂鬱、焦慮及物質使用障礙的症狀上，有顯著改善。
Patients have reported significant improvements in symptoms related to depression, anxiety, and substance use disorders.
由於大腦調節情緒與動機的區域存在GLP-1受體，這些藥物可能有助於抑制「食物噪音」(food noise)並調節多巴胺濃度。
Because GLP-1 receptors are found in brain regions regulating mood and motivation, these drugs might help quiet "food noise" and modulate dopamine levels.
此外，它們可能減少全身性發炎，這對大腦健康至關重要。
Furthermore, they may reduce systemic inflammation, which is vital for brain health.
相反地，它們最好配合專業心理諮商使用，以處理腸腦軸的複雜本質及整體福祉。
Instead, they are best utilized alongside professional psychological support to address the complex nature of the gut-brain axis and overall well-being.
